Cell No. : Cell Name
RCB1185 : TT1TKB
update : 2022/07/22
|
| Comment | Rectal carcinoma from a Japanese patient. Application consideration |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Ohno, T. & Todoroki, T.
|
| Originator |
Ohno, T.
|
| Year of deposit |
1995
|
| Another name |
ShFu
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Tissue |
rectum
|
| Disease name |
Rectal cancer
|
| Classification |
cancer
|
| Year of origin |
1995
|
| Memo_1 |
Mycoplasma was eliminated with MC-210.
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_8764
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/7-10 days, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
68-75(50) : 68(3),69(4),70(7),71(8),72(16),73(8)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
6
|
| User's Publication |
|
22103
Bian Y, Shan G, Bi G, Liang J, Hu Z, Sui Q, Shi H, Zheng Z, Yao G, Wang Q, Fan H, Zhan C.
Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis.
Redox Biol
2024
77:103361
PubMed ID: 39317105
DOI: 10.1016/j.redox.2024.103361
|
|
22703
Triboulet R, Sadykov K, Harvey DM, Wilson DM, Steinbaugh MJ, Mayo CB, Hawley D, Madanjian A, Fyfe C, Bracken C, Rivera-Rivera I, Ericsson A, Snyder AR, Knutson SK, Stein RL, Gibaja V, Ghosh S, Campbell RM.
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
Mol Cancer Ther
2024
23(12):1779-1788
PubMed ID: 39235218
DOI: 10.1158/1535-7163.MCT-24-0176
|
|
3739
Bacac M et al
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Clin Cancer Res
2016
22(13):3286-97
PubMed ID: 26861458
DOI: 10.1158/1078-0432.CCR-15-1696
|
|
15078
Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, Ishiguro A, Kijima H, Mimura J, Itoh K, Fukuda S, Saijo Y.
Methylation of the KEAP1 gene promoter region in human colorectal cancer
BMC Cancer
2012
12:66
PubMed ID: 22325485
DOI: 10.1186/1471-2407-12-66
|
|
7823
Matsuo T, Nishizuka SS, Ishida K, Iwaya T, Ikeda M, Wakabayashi G.
Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models.
BMC Res Notes
2011
4:140
PubMed ID: 21554739
DOI: 10.1186/1756-0500-4-140
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
Back
Top
CELL BANK Website
